<DOC>
	<DOCNO>NCT00961857</DOCNO>
	<brief_summary>A two-part study demonstrate bioequivalence single dose Final Market Image ( FMI ) sitagliptin /metformin ( 50/500 50/1000 mg ) Fixed-Dose Combination ( FDC ) tablet co-administration single dose sitagliptin ( 50 mg ) metformin ( 500 1000 mg ) individual tablet . Subject participate one part , receive treatment A B ( Part I ) Treatment C D ( Part II ) .</brief_summary>
	<brief_title>A Study Demonstrate Bioequivalence Sitagliptin/Metformin Combination Tablets Concomitant Administration Sitagliptin Metformin Individual Tablets ( 0431A-048 )</brief_title>
	<detailed_description />
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Female subject reproductive potential test negative pregnancy agree use appropriate contraception Subject good health nonsmoker Subject willing avoid strenuous physical activity study Subject agree refrain eat grapefruit grapefruit product study Subject history neoplastic disease ( cancer ) , stroke , chronic seizure , major neurological disorder . Subject history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality diseases Subject consumes excessive amount alcohol caffeinated beverage Subject donate blood , surgery participate another clinical study within past 4 week Subject history significant multiple and/or severe allergy prescription nonprescription drug food Subject history hypersensitivity metformin , sitagliptin , sitagliptin/Metformin Subject regular user past abuser illicit drug Subject unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy study . Subject nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>